• 1
    Lotz JC, Cheal EJ, Hayes WC 1991 Fracture prediction for the proximal femur using finite element models: Part I—linear analysis. J Biomech Eng 113:35360.
  • 2
    Bouxsein ML, Courtney AC, Hayes WC 1995 Ultrasound and densitometry of the calcaneus correlate with the failure loads of cadaveric femurs. Calcif Tissue Int 56:99103.
  • 3
    Cheng XG, Nicholson PH, Boonen S, Lowet G, Brys P, Aerssens J, Van Der Peere G, Dequeker J 1997 Prediction of vertebral strength in vitro by spinal bone densitometry and calcaneal ultrasound. J Bone Miner Res 12:17211728.
  • 4
    Marshall D, Johnell O, Wedel H 1996 Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:12541259.
  • 5
    Hui SL, Slemenda CW, Johnston CC Jr 1988 Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81:18041809.
  • 6
    Selby PL, Davies M, Adams JE 2000 Do men and women fracture bones at similar bone densities? Osteoporos Int 11:153157.
  • 7
    Orwoll E 2002 Perspective: Assessing bone density in men. J Bone Miner Res 15:18671870.
  • 8
    Cooley H, Jones G 2001 A population-based study of fracture incidence in southern Tasmania: Lifetime fracture risk and evidence for geographic variations within the same country. Osteoporos Int 12:124130.
  • 9
    Gullberg G, Johnell O, Kanis JA. Gullberg B, Johnell O, Kanis JA 1997 World-wide projections for hip fracture. Osteoporos Int 7:407413.
  • 10
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:15351541.
  • 11
    Chesnut CH III, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D 2000 A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures study. Am J Med 102:267276.
  • 12
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene—results from a 3-year randomized clinical trial. JAMA 282:637645.
  • 13
    Reginster J-Y, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:8391.
  • 14
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH, Mellstrom D, Oefjord ES, Marcinowska-Suchowierska E, Salmi J, Mulder H, Halse J, Sawicki AZ 2001 Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:14341441.
  • 15
    Watts NB, Adami S, Chesnut CH 2001 Risedronate reduces the risk of clinical vertebral fractures in just 6 months. J Bone Miner Res 16:S1;S407.
  • 16
    Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR 2000 Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 85:41184124.
  • 17
    Maricic M 2002 Raloxifene reduces vertebral fractures at one year. Arthritis Rheum 43(Suppl):S197. (abstract)
  • 18
    Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Muslin T, Thompson D, for the Fracture Intervention Trial Research Group. 1999 Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 42:12461254.
  • 19
    McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Wasnich RD, Greenwald M, Kaufman J-M, Chesnut CH, Reginster J-Y 2001 Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333340.
  • 20
    Sarkar S, Mitlak BH, Wong MM, Stock JL, Black DM, Harper KD 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:110.
  • 21
    Consensus Development Conference. 1991 Prophylaxis and treatment of osteoporosis. Am J Med 90:107110.
  • 22
    Ross PD, Davis JW, Epstein RS, Wasnich RD 1991 Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 114:919923.
  • 23
    Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E. 2001 Risk of new vertebral fracture in the year following a fracture. JAMA 285:320323.
  • 24
    Borah B, Dufresne TE, Chmielewski PA, Gross GJ, Prenger MC, Phipps RJ 2002 Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional micro-computed tomography. J Bone Miner Res 17:11391147.
  • 25
    Watts N, Bockman R, Smith C, Li Z, Eastell R, Pack S, Lindsay R 2000 BMD change explains only a fraction of the observed fracture risk reduction in risedronate-treated patients. Osteoporos Int 11(Suppl 2):S202. (abstract)
  • 26
    Riggs BL, Melton LJ III 2002 Bone turnover matters: The raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 17:1114.
  • 27
    Chesnut CH III, Rosen C 2001 Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 17:21632172.